In short – not a lot in the short-term. The vote in favour of a 0.3% THC limit by the European Parliament (EP) is only the first step in a long process towards actually putting such a change into effect.
The US Food and Drink Administration (FDA) has issued a warning letter to the CBD company For Our Vets over COVID-19 health claims
Holiday sales overall mean more to US companies than their UK counterparts, but the novelty of Black Friday means some are embracing a discount period as a means to create new sales, according to a number of companies
The company of the president of the European Industrial Hemp Association (EIHA) has challenged a ban on the sale of all foods containing CBD
Nestlé has taken a baby step into the European cannabidiol market just a year after creating its own CBD line in the US and will now distribute soft gel CBD capsules in the UK through the Pure Encapsulations brand
Our host for today’s podcast is Jon Bruford, a copy editor at CBD-Intel, who will be joined by CBD-Intel market analyst Maria Alejandra Estanga, who analyses the CBD market for European and American countries. In CBD-Intel’s new podcast, Alejandra discusses global CBD markets and their commonalities and differences, analysing each market and its own peculiarities […]
In an unheralded change of Amazon policy, the world’s biggest online marketplace has started allowing the sale of CBD products on its UK site
Matches in Serie A, the top football league in Italy, are for the first time featuring advertisements for a CBD company as the home delivery market continues to grow rapidly in the country
A legal action against Canopy Growth has been halted now that Canadian cannabis cultivator PharmHouse has filed for bankruptcy protection from the Ontario Court while it restructures its business
Commercial interest in mushrooms as active ingredients is on the rise – despite legal issues that severely curtail commercial opportunities
Turbulent times and the ongoing challenges caused by COVID-19 are not stopping some CBD businesses from doing deals and making major investments as they seek expansion into new markets
There has been increased interest in secondary markets that has resulted in some positive developments.
Maria Alejandra Estanga, our market analysts, presented the current status of the topicals market across the most important CBD markets during the Virtual Cannacosmo Health + Beauty Expo on 29st September.
US-based CBD producer Folium Biosciences is looking to tap Asian markets by creating a dedicated stalk extraction line which it believes will meet the strict regulatory requirements of Japan and South Korea
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
2020 seems an unlikely year for the emergence of any new industry, yet this is exactly what has happened in Hong Kong, where there are now locally produced CBD food and drink products
A TV advertising campaign for US company cbdMD demonstrates how attitudes towards CBD products are slowly changing in advertising circles – but also how much work remains to be done
Britain’s newfound enthusiasm for CBD products has joined with the passion for alcohol, with some companies are aiming to capitalise on the trend for “drinking less but drinking better” by launching CBD spirits, especially gin
CBD firms are expanding their reach into the wellness market via company acquisitions, distribution deals and new product launches
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
Companies seeking licences to produce hemp in the Chinese province of Yunnan face a tightening of the application process, according to some who have successfully negotiated the concealed hurdles
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
The bankruptcy stories continue for cannabinoid firms in the US and Canada as businesses struggle to survive in turbulent times
Molson Coors has made its long awaited entry into the cannabis market through the launch of its Truss brand of cannabis drinks made in partnership with cannabis company Hexo
The immediate impact of the decision is a reduction in certainty for CBD firms – not something they need at a time of significantly heightened uncertainty in other areas.
Charlotte’s Web has been denied a US trademark on appeal – a ruling that has serious implications for any company in the CBD sector selling food, drink or dietary supplement products in the US
Expansion plans by two major players suggest confidence in the future of the CBD market in the UK, with one anticipating a continuing rise in sales driven by reactions to the COVID-19 pandemic
A German company is still waiting to hear from the authorities two months after launching new CBD products that could be considered food supplements
The trade body for hemp and CBD in Ireland has accused the Irish government of working in silos and said its lack of intra-governmental communication as well as consultation with stakeholders could lead to the end of the industry in the country
Maria Alejandra Estanga, one of CBD-Intel’s market analysts, presented the latest CBD market trends & country comparison at the CBD live during VOXPO – Virtual Online Vape & CBD Expo on 31st July.
A new special purpose acquisition company (SPAC) operating in the hemp space is expected to start making moves in the near future after raising $150m earlier this year
A US CBD company has taken an unusual approach to advertising to set itself apart from the pack. It is using a spare forceful campaign that actively discourages some people from using its products
Registration in the US FDA National Drug Code (NDC) Directory conveys significant benefits even if the FDA does not specifically approve these items as over-the-counter products, according to a CBD company
Current indications are that the EC is leaning heavily towards the idea that CBD does indeed count as a narcotic under the 1961 Un Convention.
Canadian CBD firm Ignite lost $67m CAD last year and it could go under if it doesn’t get funding soon, auditors warned in an annual report
As tough market conditions continue for cannabinoid firms in the US and Canada, struggling companies are continuing to pursue a range of survival strategies
Current indications are that the EC is leaning heavily towards the idea that CBD does indeed count as a narcotic under the 1961 Un Convention.
Firms from Israel and South America are showing faith in the European CBD market, and its bricks-and-mortar retail, with distribution deals to place their products in a growing number of outlets
Global agricultural giant Pyxus International is among a number of international companies that have expressed interest in venturing into hemp cultivation in Malawi
A TV advertising campaign has significantly boosted sales for a CBD drinks company and it hopes a new listing in a high-end chain of UK supermarkets will consolidate those gains
It remains unclear where the hemp and CBD investment centre for Asia will develop. History and existing infrastructure would point to Hong Kong, but development there has stalled – and there are other contenders
Enforcement activity against food, drink and dietary supplement products placed on the market containing CBD continues despite the inability of companies to proceed with novel food applications due to the EC’s questions over whether CBD constitutes a narcotic under the 1961 UN Single Convention on Narcotics.
Hard-hit cannabinoid firms in the US and Canada are reassessing their market strategies, restructuring, and downsizing – in some cases with significant job cuts – as the market remains volatile
Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.
This report investigates the current situation with respect to advertising CBD products via the most widely used social media platforms
A strong online presence has been essential to resiliency through the COVID-19 pandemic, but many larger offline retail chains that have also focused on selling through these channels may still see a recovery
The loss of conferences and expos due to COVID-19 prevention measures has not affected the sale of white label goods as much as may have been anticipated, according to companies
CBD companies are in a fairly unique place in that they cannot use their primary function – health and wellness – to advertise their brands. And this is not without reason – as shown by the numerous instances of scurrilous companies making outlandish claims about CBD and cancer, Alzheimer’s and other diseases where a “miracle cure” is seemingly often the last chance of the desperate.
In a case that illustrates difficulties a number of CBD businesses have encountered in reaching their target market, a CBD company in the US is suing a TV advertising firm, alleging deceptive trade practices and breach of contract
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.
Free sample available
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
